INFECTIVITY AND PATHOGENESIS OF TISSUE CULTURE DERIVED HCV IN CHIMPANZEES

黑猩猩组织培养 HCV 的感染性和发病机制

• 批准号: 7957961
• 负责人: Krishna K Murthy
• 金额: $ 4.67万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-06-06 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7957961
• 关键词: Animals; Biological Assay; Biopsy Specimen; Blood; Computer Retrieval of Information on Scientific Projects Database; Development; Disease; Dose; Funding; Genotype; Grant; Hepatitis C; Hepatitis C virus; Human; In Vitro; Infection; Institution; Methodology; Modeling; Monitor; Pan Genus; Pathogenesis; Pharmaceutical Preparations; Plasma; Preparation; Prevention; Primates; Research; Research Personnel; Resources; Sampling; Source; Testing; Time; United States National Institutes of Health; Virus; liver biopsy; tissue culture; vaccine candidate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recent advances in HCV research has resulted in the development of in vitro tissuelcell culture methodologies for the replication of HCV. It is not clear whether all of the in vitro derived HCV isolates retain their infectivity and disease causing ability. The proposed studies will determine whether certain in vitro derived isolates of HCV are infectious and cause pathogenesis in the chimpanzee model. One to two animals at a time will be injected with a particular isolate of HCV and will be monitored for evidence of infection by PCR analysis using plasma samples. If there is evidence of infection then additional blood and liver biopsy samples will be obtained for virological and immunological assays. If there is no evidence of infection, then the animals will be injected with a higher dose of the same isolate or a different isolate and monitored for infection as described earlier. Pedigreed and well characterized stocks of HCV genotype 1 and 2 virus tocks are essential to test antivial activity of new drugs that are being developed for treating HCV infected humans. In addition, the stock virus preparations can be used to determine the efficacy of candidate vaccines that are being developed for prevention of HCV infection.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 HCV研究的最新进展导致了用于复制HCV的体外组织培养方法的发展。目前尚不清楚所有体外衍生的HCV分离株是否保留其感染力和疾病引起的能力。拟议的研究将确定某些HCV的体外衍生分离株是否具有感染性并在黑猩猩模型中引起发病机理。一次将一到两只动物注射特定的HCV分离株，并将通过使用血浆样品进行PCR分析来监测以获取感染的证据。如果有感染的证据，则将获得其他血液和肝活检样本 病毒学和免疫学测定。如果没有感染的迹象，则将为动物注射较高剂量的相同分离株或不同的分离株，并如前所述监测感染。 HCV基因型1和2病毒TOCK的谱系且特征良好的库存对于测试用于治疗HCV感染人类的​​新药的抗生活性至关重要。此外，可以使用库存病毒制剂来确定正在开发用于预防HCV感染的候选疫苗的功效。